Print

AVEG 034/034A

A Phase I Trial to Compare the Safety and Immunogenicity of Three Live Recombinant Canarypox ALVAC-HIV Vaccines vCP205, vCP1433 and vCP1452, in HIV-1 Uninfected Adult Volunteers

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) June 17, 1998
ALVAC vCP1433,ALVAC vCP1452,ALVAC-HIV MN120TMG strain (vCP205) Canarypox env, gag, pol B; Canarypox env, gag, pol B; Canarypox Env gp120, TM gp41, gag, protease B MN/LAI
ALVAC vCP1433 Viral Vector - Pox
ALVAC vCP1452 Viral Vector - Pox
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
USA 100
NCT00000904
https://clinicaltrials.gov/show/NCT00000904